ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1,2,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2,3,Musculoskeletal discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2,5,Tachypnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3,2,Haemodynamic instability,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
3,3,Neurological symptom,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3,4,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,Y
4,2,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4,3,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
5,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
6,1,Duodenal perforation,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
7,1,Duodenal perforation,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,Y
7,2,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
7,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
7,4,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
8,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
8,2,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
8,3,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
9,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
9,2,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
9,3,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
10,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
10,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
11,1,Metastatic neoplasm,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
12,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
13,1,Myocarditis,Noninfectious myocarditis,Myocardial disorders,Card,Y
14,1,Cerebral palsy,Cerebral disorders congenital,Neurological disorders congenital,Cong,N
14,2,Metastasis,Metastases to unknown and unspecified sites,Metastases,Neopl,N
15,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
15,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
16,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
17,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
18,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
18,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
19,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
19,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
20,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
20,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
21,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
21,2,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
22,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
22,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
22,3,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
23,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
23,2,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
23,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
23,4,Slow response to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
24,1,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
24,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
24,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
25,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
26,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
27,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
27,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
27,3,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
27,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
28,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
28,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
28,3,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
28,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
29,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
29,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
30,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
30,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
31,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
32,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
32,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
33,1,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
33,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
34,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
34,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
34,3,Respiration abnormal,Breathing abnormalities,Respiratory disorders NEC,Resp,N
35,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
35,2,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
35,3,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
35,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
35,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
35,6,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
36,1,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
36,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
36,3,Respiration abnormal,Breathing abnormalities,Respiratory disorders NEC,Resp,N
37,1,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
37,2,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
37,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
37,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
38,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
39,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
39,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
39,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
39,4,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
39,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
39,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
39,7,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
39,8,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
39,9,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
39,10,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
39,11,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
40,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
41,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
41,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
41,3,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
41,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
41,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
41,6,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
41,7,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
42,1,Autoimmune neutropenia,Neutropenias,White blood cell disorders,Blood,N
42,2,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
42,3,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
42,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
42,5,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
43,1,Aplastic anaemia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
43,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
43,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
44,1,Aplastic anaemia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
45,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
46,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
47,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
48,1,Administration site extravasation,Administration site reactions NEC,Administration site reactions,Genrl,N
49,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
50,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
51,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
52,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
53,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
54,1,Gingivitis,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
55,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
56,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
56,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
56,3,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
56,4,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
57,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
58,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
59,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
60,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
61,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
62,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
62,2,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
63,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
63,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
63,3,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
64,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
65,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
65,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
66,1,Sensory disturbance,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
67,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
67,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
68,1,Sensory disturbance,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
69,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
69,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
70,1,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
70,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
71,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
71,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
72,1,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
72,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
73,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
73,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
74,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
74,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
74,3,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
75,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
76,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
77,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
78,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
79,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
79,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
80,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
80,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
80,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
80,4,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
81,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
82,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
83,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
84,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
85,1,Blood thyroid stimulating hormone decreased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
85,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
85,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
85,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
85,5,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
85,6,Hypophysitis,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
85,7,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
86,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
86,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
87,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
87,2,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
88,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
89,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
89,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
89,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
89,4,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
89,5,Hypophysitis,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
89,6,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
90,1,Nephritis,Nephritis NEC,Nephropathies,Renal,N
91,1,Nephritis,Nephritis NEC,Nephropathies,Renal,N
92,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
92,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
93,1,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
94,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
95,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
95,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
96,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
96,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
97,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
97,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
98,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
98,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
99,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
100,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
101,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
102,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
103,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
104,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
104,2,Eastern Cooperative Oncology Group performance status worsened,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
104,3,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
105,1,Polycythaemia,Polycythaemia (excl rubra vera),Red blood cell disorders,Blood,N
106,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
107,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
108,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
109,1,Polycythaemia,Polycythaemia (excl rubra vera),Red blood cell disorders,Blood,N
110,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
111,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
111,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
111,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
112,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
113,1,Polycythaemia,Polycythaemia (excl rubra vera),Red blood cell disorders,Blood,N
114,1,Polycythaemia,Polycythaemia (excl rubra vera),Red blood cell disorders,Blood,N
115,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
116,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
117,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
118,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
118,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
118,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
118,4,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
118,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
118,6,Headache,Headaches NEC,Headaches,Nerv,N
118,7,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
118,8,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
118,9,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
119,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
120,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
120,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
120,3,Blood thyroid stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
120,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
120,5,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
120,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
120,7,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
120,8,Thyroxine abnormal,Thyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
121,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
121,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
122,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
122,2,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
122,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
122,4,Gastrointestinal motility disorder,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
122,5,Headache,Headaches NEC,Headaches,Nerv,N
122,6,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
122,7,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
122,8,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
123,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
124,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
125,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
126,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
127,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
128,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
129,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
129,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
130,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
130,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
131,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
132,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
133,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
134,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
135,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
136,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
137,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
137,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
137,3,Blood thyroid stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
137,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
137,5,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
137,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
137,7,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
138,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
138,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
139,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
139,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
140,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
141,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
142,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
143,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
144,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
145,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
146,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
147,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
148,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
149,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
149,2,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
150,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
151,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
151,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
151,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
151,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
151,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
151,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
151,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
152,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
152,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
152,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
153,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
153,2,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
153,3,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
153,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
153,5,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
154,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
155,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
155,2,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
155,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
156,1,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
157,1,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
158,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
158,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
159,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
159,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
159,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
160,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
160,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
161,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
161,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
162,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
163,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
163,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
163,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
164,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
164,2,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
165,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
165,2,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
165,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
165,4,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
165,5,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
165,6,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
165,7,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
165,8,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
165,9,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
165,10,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
166,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
167,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
168,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
168,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
168,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
168,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
168,5,Pulmonary hilum mass,Mediastinal disorders,Thoracic disorders (excl lung and pleura),Resp,N
168,6,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
169,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
170,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
171,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
171,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
171,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
171,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
171,5,Pulmonary hilum mass,Mediastinal disorders,Thoracic disorders (excl lung and pleura),Resp,N
171,6,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
172,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
172,2,Atrial enlargement,Myocardial disorders NEC,Myocardial disorders,Card,N
172,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
172,4,Coronary artery occlusion,Coronary artery disorders NEC,Coronary artery disorders,Card,N
172,5,Dermatitis acneiform,Acnes,Skin appendage conditions,Skin,N
172,6,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
172,7,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
172,8,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
172,9,Electrocardiogram Q wave abnormal,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
172,10,Electrocardiogram ST segment elevation,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
172,11,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
172,12,Mitral valve incompetence,Mitral valvular disorders,Cardiac valve disorders,Card,N
172,13,Systolic dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
172,14,Troponin increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
173,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
173,2,Dermatitis acneiform,Acnes,Skin appendage conditions,Skin,N
173,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
173,4,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
173,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
174,1,Atrial enlargement,Myocardial disorders NEC,Myocardial disorders,Card,N
174,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
174,3,Coronary artery occlusion,Coronary artery disorders NEC,Coronary artery disorders,Card,N
174,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
174,5,Electrocardiogram ST segment elevation,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
174,6,Mitral valve incompetence,Mitral valvular disorders,Cardiac valve disorders,Card,N
174,7,Systolic dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
174,8,Troponin increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
175,1,Anal abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
175,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
175,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
175,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
175,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
175,6,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
175,7,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
175,8,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
175,9,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
175,10,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
175,11,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
176,1,Blood thyroid stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
176,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
176,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
177,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
177,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
178,1,Blood potassium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
178,2,Blood sodium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
178,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
179,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
180,1,Blood potassium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
180,2,Blood sodium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
180,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
181,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
181,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
181,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
181,4,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
181,5,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
182,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
183,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
183,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
184,1,Hemianopia heteronymous,Neurologic visual problems NEC,Neurological disorders of the eye,Nerv,N
185,1,Blood thyroid stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
185,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
185,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
186,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
187,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
187,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
187,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
187,4,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
187,5,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
188,1,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
189,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
189,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
189,3,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
190,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
190,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
191,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
191,2,Faeces soft,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
191,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
192,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
192,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
193,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
194,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
194,2,Headache,Headaches NEC,Headaches,Nerv,N
194,3,Headache,Headaches NEC,Headaches,Nerv,N
194,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
194,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
194,6,Spinal pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
195,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
195,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
195,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
196,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
197,1,Psoriatic arthropathy,Psoriatic arthropathies,Joint disorders,Musc,N
198,1,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
199,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
199,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
200,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
200,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
201,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
201,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
201,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
202,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
202,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
203,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
203,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
204,1,Encephalitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
205,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
205,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
206,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
207,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
207,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
207,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
208,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
208,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
208,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
209,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
210,1,Encephalitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
211,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
211,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
211,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
212,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
212,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
212,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
213,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
213,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
214,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
214,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
215,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
215,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
215,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
215,4,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
215,5,Respiratory arrest,Breathing abnormalities,Respiratory disorders NEC,Resp,N
215,6,Rib fracture,Thoracic cage fractures and dislocations,Bone and joint injuries,Inj&P,N
215,7,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
216,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
216,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
217,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
218,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
218,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
219,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
219,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
220,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
220,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
220,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
221,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
222,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
222,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
223,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
223,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
224,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
224,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
225,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
226,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
227,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
228,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
229,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
229,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
230,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
231,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
232,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
232,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
232,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
233,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
233,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
233,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
234,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
234,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
234,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
235,1,Apathy,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
235,2,Eastern Cooperative Oncology Group performance status worsened,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
236,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
236,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
237,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
237,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
238,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
238,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
239,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
239,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
240,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
240,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
240,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
241,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
241,2,Impaired quality of life,Social issues NEC,Lifestyle issues,SocCi,N
242,1,Apathy,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
242,2,Eastern Cooperative Oncology Group performance status worsened,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
243,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
244,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
245,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
246,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
247,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
247,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
248,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
249,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
250,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
251,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
251,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
252,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
252,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
253,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
254,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
254,2,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
255,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
255,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
256,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
256,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
257,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
257,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
257,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
258,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
258,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
259,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
259,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
260,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
260,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
260,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
261,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
261,2,Metastatic renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
261,3,Papillary renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
262,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
262,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
262,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
263,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
263,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
263,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
264,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
264,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
264,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
265,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
265,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
266,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
266,2,Drug titration error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
266,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
267,1,Adverse reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
267,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
268,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
269,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
270,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
271,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
271,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
272,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
272,2,Migraine,Migraine headaches,Headaches,Nerv,N
273,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
273,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
273,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
274,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
274,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
274,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
275,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
275,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
275,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
276,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
276,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
277,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
277,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
277,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
278,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
278,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
279,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
279,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
280,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
281,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
282,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
283,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
284,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
285,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
286,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
287,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
288,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
289,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
290,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
291,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
291,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
292,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
293,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
294,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
294,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
294,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
294,4,Impaired quality of life,Social issues NEC,Lifestyle issues,SocCi,N
295,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
295,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
295,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
296,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
296,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
297,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
298,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
299,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
299,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
300,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
301,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
302,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
302,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
303,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
303,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
304,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
304,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
304,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
305,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
305,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
306,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
307,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
308,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
309,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
309,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
310,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
311,1,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
311,2,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
312,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
313,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
314,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
315,1,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
316,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
316,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
316,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
316,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
317,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
318,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
319,1,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
319,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
319,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
320,1,Arteriosclerosis,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
320,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
320,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
320,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
321,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
322,1,Arteriosclerosis,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
322,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
322,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
322,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
323,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
324,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
325,1,Gastrointestinal toxicity,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
326,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
326,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
327,1,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
328,1,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
329,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
329,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
330,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
331,1,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
332,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
333,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
334,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
334,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
334,3,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
335,1,Hypopituitarism,Anterior pituitary hypofunction,Hypothalamus and pituitary gland disorders,Endo,N
336,1,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
337,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
338,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
339,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
339,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
339,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
340,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
341,1,Endocrine disorder,Endocrine disorders NEC,Endocrine and glandular disorders NEC,Endo,N
341,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
342,1,Infusion related hypersensitivity reaction,Allergic conditions NEC,Allergic conditions,Immun,N
343,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
344,1,Immune-mediated neurological disorder,Central nervous system inflammatory disorders NEC,Central nervous system infections and inflammations,Nerv,N
344,2,Paraneoplastic neurological syndrome,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
344,3,Tumour hyperprogression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
345,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
346,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
347,1,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
348,1,Immune-mediated nephritis,Nephritis NEC,Nephropathies,Renal,N
348,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
349,1,Immune-mediated nephritis,Nephritis NEC,Nephropathies,Renal,N
349,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
350,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
350,2,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
350,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
350,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
351,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
352,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
352,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
352,3,Cortisol decreased,Adrenal cortex tests,Endocrine investigations (incl sex hormones),Inv,N
352,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
352,5,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
352,6,Myocarditis,Noninfectious myocarditis,Myocardial disorders,Card,N
352,7,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
352,8,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
352,9,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
352,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
353,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
353,2,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
353,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
353,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
354,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
354,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
354,3,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
354,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
354,5,Retinal vein occlusion,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
355,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
356,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
356,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
356,3,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
356,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
356,5,Retinal vein occlusion,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
357,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
357,2,Neoplasm recurrence,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
357,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
358,1,Encephalitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,Y
358,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
358,3,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
359,1,Large intestine polyp,Benign neoplasms gastrointestinal (excl oral cavity),Benign neoplasms gastrointestinal,Gastr,N
360,1,Bronchitis,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
360,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
360,3,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
361,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
361,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
361,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
361,4,Seborrhoeic dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
362,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
362,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
362,3,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
363,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
363,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
364,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
364,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
365,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
365,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
365,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
365,4,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
366,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
367,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
367,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
367,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
367,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
368,1,Type 1 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
369,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
369,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
369,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
369,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
369,5,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
369,6,Mental fatigue,Cognitive and attention disorders and disturbances NEC,Cognitive and attention disorders and disturbances,Psych,N
370,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
370,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
370,3,Transaminases abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
371,1,Transaminases abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
372,1,Immune-mediated lung disease,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
373,1,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
374,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
375,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
376,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
377,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
378,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
379,1,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
380,1,Immune-mediated cystitis,Bladder infections and inflammations,Bladder and bladder neck disorders (excl calculi),Renal,N
381,1,Guillain-Barre syndrome,Acute polyneuropathies,Peripheral neuropathies,Nerv,N
381,2,Miller Fisher syndrome,Acute polyneuropathies,Peripheral neuropathies,Nerv,N
382,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
382,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
383,1,Immune-mediated hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
384,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
384,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
385,1,Folliculitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
386,1,Myocarditis,Noninfectious myocarditis,Myocardial disorders,Card,Y
387,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
387,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
387,3,Eye symptom,Ocular disorders NEC,Eye disorders NEC,Eye,N
387,4,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
387,5,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
387,6,Myocarditis,Noninfectious myocarditis,Myocardial disorders,Card,N
387,7,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
387,8,Nephritis,Nephritis NEC,Nephropathies,Renal,N
388,1,Tubulointerstitial nephritis,Nephritis NEC,Nephropathies,Renal,N
389,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
390,1,Myasthenia gravis,Neuromuscular junction dysfunction,Neuromuscular disorders,Nerv,N
390,2,Myocarditis,Noninfectious myocarditis,Myocardial disorders,Card,Y
390,3,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
391,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
392,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
393,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
393,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
393,3,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
394,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
